Abstract
Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Biologic Agents for Treatment of Rheumatoid Arthritis
Volume: 9 Issue: 1
Author(s): Bulent Butun
Affiliation:
Keywords: Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab
Abstract: Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.
Export Options
About this article
Cite this article as:
Butun Bulent, Biologic Agents for Treatment of Rheumatoid Arthritis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711692
DOI https://dx.doi.org/10.2174/187152310790711692 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn
Current Immunology Reviews (Discontinued) Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes
Current Stem Cell Research & Therapy A Concise Review on Multidimensional Silver Nanoparticle Health Aids and Threats
Current Drug Therapy Editorial [Hot Topic: Stem Cell Based Therapy for Autoimmunity (Guest Editor: Frank Alderuccio)]
Current Stem Cell Research & Therapy Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer
Current Medicinal Chemistry Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry Retracted: Effects of Vitamin K2 on Osteoporosis
Current Pharmaceutical Design Circulating Osteoclast Precursors: A Mechanism and a Marker of Erosive Arthritis
Current Rheumatology Reviews Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry The Effects of Hydroalcoholic Extract from Alhagi on Matrix Metalloproteinase- 9 Production in Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis
The Natural Products Journal In vitro And In vivo Immunomodulating Properties of Mesenchymal Stem Cells
Recent Patents on Inflammation & Allergy Drug Discovery Transglutaminase-Catalyzed Reactions Responsible for the Pathogenesis ofCeliac Disease and Neurodegenerative Diseases: From Basic Biochemistry to Clinic
Current Medicinal Chemistry Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Current Medicinal Chemistry Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) NF-κB in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Current Rheumatology Reviews Bisphosphonates-Anti-Inflammatory Properties
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Adult Stem Cells in Bone and Cartilage Tissue Engineering
Current Stem Cell Research & Therapy CXC Chemokines in Angiogenesis Relevant to Chronic Fibroproliferation
Current Drug Targets - Inflammation & Allergy Paracetamol (Acetaminophen) Efficacy and Safety in the Newborn
Current Drug Metabolism